Renal osteodystrophy is currently defined as an alteration of bone morphology in patients with chronic kidney disease (CKD). It is one measure of the skeletal component of the systemic disorder of chronic kidney disease-mineral and bone disorder (CKD-MBD).

Osteodystrophy is any dystrophic growth of the bone. It is defective bone development that is usually attributable to renal disease or to disturbances in calcium and phosphorus metabolism. One form is renal osteodystrophy.Treatment for renal osteodystrophy includes the drug cinacalcet hydrochloride (Sensipar), and synthetic calcitriol and calcium supplements. Proper diet and exercise can also help.

When kidneys do not function properly, extra parathyroid hormone is released in the blood to move calcium from inside the bones into the blood. Chronic kidney disease causes mineral and bone disorder because the kidneys do not properly balance the mineral levels in the body.Usually, overactive parathyroid glands are controllable with a change in diet, dialysis treatment, or medication. The drug cinacalcet hydrochloride (Sensipar), approved by the Food and Drug Administration in 2004, lowers PTH levels by imitating calcium. ... Renal osteodystrophy can also be treated with changes in diet.